Drugs / ATECEGATRAN METOXIL
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT00904800 | May → Jun 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00878618 | Apr → May 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00812643 | Jan → Feb 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00812344 | Dec 2008 → Mar 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT00645853 | Oct 2007 → May 2009 | persistent atrial fibrillation | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00623779 | Oct 2007 → Oct 2008 | persistent atrial fibrillation | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00684307 | Feb 2007 → Jun 2008 | atrial fibrillation | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATECEGATRAN METOXIL | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297593 ↗ |
| Known as | Atecegatran fexenetil | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297593 ↗ |
| Known as | Atecegatran metoxilo | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297593 ↗ |
| Known as | AZD0837 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00623779 ↗ |
| Action | Inhibit | “oral direct thrombin inhibitor” NCT00645853 ↗1“Thrombin inhibitor” CHEMBL4297593 ↗ |
| Modality | Small molecule | — CHEMBL4297593 ↗ |
| Route | Oral | “Oral Direct Thrombin Inhibitor, AZD0837” NCT00623779 ↗ |
| Target | F2 | “Thrombin inhibitor” CHEMBL4297593 ↗ |